Walsh, M., Merkel, P.A., Peh, C.A., Szpirt, W.M., Puéchal, X., Fujimoto, S., Hawley, C.M., Khalidi, N., Floßmann, O., Wald, R., Girard, L.P., Levin, A., Gregorini, G., Harper, L., Clark, W.F., Pagnoux, C., Specks, U., Smyth, L., Tesar, V., Ito-Ihara, T., de Zoysa, J.R., Szczeklik, W., Flores-Suárez, L.F., Carette, S., Guillevin, L., Pusey, C.D., Casian, A.L., Brezina, B., Mazzetti, A., McAlear, C.A., Broadhurst, E., Reidlinger, D., Mehta, S., Ives, N., Jayne, D.R.W., for the PEXIVAS Investigators (2020) Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. The New England Journal of Medicine, 382, 622-631.
https://doi.org/10.1056/NEJMoa1803537

has been cited by the following article:

• TITLE: ANCA-Associated Vasculitis: Value of Apheresis in Initial Treatment

  AUTHORS: Djibrilla Bonkano, Hassane Moussa Diongolé, Hamza Naciri Bennani, Johan Noble, Paolo Malvezzi, Lionel Rostaing

  KEYWORDS: ANCA-Associated Vasculitis, Apheresis, Rituximab, Remission, Rapidly Progressive Glomerulonephritis

  JOURNAL NAME: Open Journal of Nephrology, Vol.12 No.2, May 19, 2022

  ABSTRACT: Introduction: Vasculitis associated with anti-neutrophil cytoplasm antibodies (ANCA) can be grouped with granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MAP), and eosinophilic granulomatosis with polyangiitis (EGPA). Diagnosis of these rare pathologies is based on clinical presentation, the positivity of ANCA, and, if possible, histological proof of vasculitis. Our study describes a series of six cases of ANCA-associated vasculitis where due to the severity of symptoms apheresis sessions were started from the beginning of the therapy. Patients and methods: We conducted a retrospective, single-center observational, monocentric study on all patients treated by apheresis for ANCA vasculitis in the period January 01, 2016 to December 01, 2019. Results: We identified six cases of ANCA vasculitis treated by apheresis over a 3-year period. The mean age was 61 ± 19 years; M/F gender ratio was 1:1. Initial renal damage in all patients was rapidly progressive glomerulonephritis. Inflammatory syndrome occurred in all patients with average CRP of 82 mg/L. All patients had positive ANCA at diagnosis. Four patients required renal replacement therapy at the time of diagnosis. The induction regimen consisted of rituximab associated with IV boluses of methylprednisolone. The apheresis techniques used were the same for all patients, i.e. plasmapheresis. Outcomes were favorable for five patients; only one patient became dependent on hemodialysis. No mortality occurred. Conclusion: This study analyzed practices for the management of patients with ANCA vasculitis. No patient was treated with cyclophosphamide as a first approach but rituximab instead. Plasmapheresis was given because of symptoms severity at initial diagnosis.